The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Time-limited combination therapies involving BTKis and BCL2is in treatment-naïve CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the use of time-limited combination therapies involving BTK inhibitors (BTKis) and BCL-2 inhibitors (BCL2is) in treatment-naïve chronic lymphocytic leukemia (CLL). She highlights combinations such as ibrutinib or acalabrutinib with venetoclax, noting their demonstrated efficacy and tolerability in clinical trials. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We started quite recently using this combination. The first one approved is the combination of ibrutinib, the first in class, plus venetoclax. At this meeting, the updated results of the CAPTIVATE trial are presented, suggesting that this combination is highly effective and can achieve long-lasting disease control, because now we reached a 5.5 year follow-up. Recently the EMA approved just a few days ago the combination of acalabrutinib plus venetoclax taking into account the data from the AMPLIFY study, so we will have a second combination available in the near future that we can use in our patient population...
We started quite recently using this combination. The first one approved is the combination of ibrutinib, the first in class, plus venetoclax. At this meeting, the updated results of the CAPTIVATE trial are presented, suggesting that this combination is highly effective and can achieve long-lasting disease control, because now we reached a 5.5 year follow-up. Recently the EMA approved just a few days ago the combination of acalabrutinib plus venetoclax taking into account the data from the AMPLIFY study, so we will have a second combination available in the near future that we can use in our patient population. As I say this is a very effective combination with the BTK inhibitor leading. The majority of patients at the time of venetoclax administration does not carry a high risk of TLS because the lymph node shrinks and there is no very high value of lymphocytes in the peripheral blood. So we can safely start the ramp up of venetoclax and administer it without experiencing relevant toxicity in terms of TLS. And we are able to achieve very deep responses that allow us to stop treatment and let the patient get some treatment-free period.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
